Sandoz Leads Charge With First US Denosumab Launch

But Several More Biosimilar Prolia/Xgeva Competitors Await

 
• By Dave Wallace
  
Sandoz is ahead of the competition with the first US denosumab biosimilar launch (Shutterstock)

More from Biosimilars

More from Business